Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Phase 2

Completed

• Conditions: Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer
• Interventions: Drug: cediranib maleate; Other: laboratory biomarker analysis

• Registration Number: NCT00278343
• Lead Sponsor: National Cancer Institute (NCI)

Brief Summary

This phase II trial is studying how well cediranib maleate works in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer. Cediranib maleate may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

Detailed Description

PRIMARY OBJECTIVES:

I. Objective tumor response rate (complete plus partial response plus stable disease \> 16 weeks as defined by the Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) in women with recurrent or refractory advanced ovarian or primary peritoneal cancer.

SECONDARY OBJECTIVES:

I. Time to disease progression, median survival time, and duration of overall cancer antigen (CA)-125 response.

OUTLINE:

Patients receive cediranib maleate orally (PO) once daily (QD) every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 4 weeks and then every 3 months thereafter.

Study Timeline

• Study First Submitted: 2006-01-16
• Study First Submitted QC: 2006-01-16
• Study First Posted: 2006-01-18
• Study Start: 2006-04
• Primary Completion: 2010-06
• Results First Submitted: 2015-09-23
• Results First Submitted QC: 2017-05-31
• Results First Posted: 2017-07-02
• Study Completion: 2018-01-15
• Status Verified: 2018-07
• Last Update Submitted: 2018-07-31
• Last Update Posted: 2018-08-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 74

Inclusion Criteria

• Patients must have histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has recurred or is refractory to initial therapy; patients must have received platinum-based chemotherapy before entry into this protocol
• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral computed tomography (CT) scan OR patients must have evidence of progression based on an elevated CA-125 (defined as a value of > 2 x upper limit of normal [ULN] documented on two separate determinations made > 2 weeks apart) if the physical exam is normal and CT scan of the chest/abdomen/pelvis, has a disease volume < 1 cm in maximum diameter
• Patients may have received no more than one prior chemotherapy regimen (i.e. initial first-line chemotherapy only)
• Life expectancy of greater than 12 weeks
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
• Leukocytes >= 3,000/mcL
• Absolute neutrophil count >= 1,500/mcL
• Platelets >= 100,000/mcL
• Hemoglobin >= 8 g/dL
• Total bilirubin within normal institutional limits
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 × institutional upper limit of normal
• Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
• Women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
• Ability to understand and the willingness to sign a written informed consent document

Read More

Exclusion Criteria

• Patients who have had chemotherapy, radiotherapy, or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
• Patients with borderline tumors or tumors of low malignant potential
• Patients with current bowel obstruction
• Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 30 days
• Patients with known brain metastases should be excluded from this clinical trial
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD2171 (cediranib maleate)
• Mean corrected QT (QTc) > 470 msec (with Bazett's correction) in screening electrocardiogram or history of familial long QT syndrome
• Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart
• Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with AZD2171
• Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
• Any significant abnormality noted in the electrocardiogram (ECG) within 14 days of treatment
• A New York Heart Association classification of III or IV (NOTE: patients classified as class II controlled with treatment may continue with increase monitoring)
• Conditions requiring concurrent use of drugs or biologics with proarrythmic potential; these drugs are prohibited during studies with AZD2171

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (cediranib maleate)	cediranib maleate	Patients receive cediranib maleate PO QD every 4 weeks in the absence of disease progression or unacceptable toxicity.
Treatment (cediranib maleate)	laboratory biomarker analysis	Patients receive cediranib maleate PO QD every 4 weeks in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria	After 16 weeks	Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>= 30% decrease in the sum of the longest diameter of target lesions; Overall Response(OR) = CR+PR

Secondary Outcome Measures

Name	Time	Method
Incidence of Toxicity Graded According to National Cancer Institution Common Terminology Criteria for Adverse Events Version 3.0	Up to 4 years
Overall Survival (OS) (Discontinued as of 4/25/2014)	From date of radomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 32 months.	The Kaplan-Meier method will be used to estimate OS. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible.
Progression-free Survival (PFS)	Time from start of treatment to time of progression, assessed up to 6 months	The Kaplan-Meier method will be used to estimate PFS. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion or the appearance of new lesions.
Duration of Overall CA-125 Response	Up to 4 years	Confirmed response on CA125 - defined as reduction in level of pre-treatment sample by \> 50%.
Time to Disease Progression	Up to 4 years	Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible.

Trial Locations

Locations (28)

City of Hope Medical Group Inc; 🇺🇸 Pasadena, California, United States

City of Hope; 🇺🇸 Duarte, California, United States

Ingalls Memorial Hospital; 🇺🇸 Harvey, Illinois, United States

Joliet Oncology-Hematology Associates Limited; 🇺🇸 Joliet, Illinois, United States

Peoria Gynecologic Oncology; 🇺🇸 Peoria, Illinois, United States

Oncology/Hematology Associates; 🇺🇸 Peoria, Illinois, United States

Central Illinois Hematology Oncology Center; 🇺🇸 Springfield, Illinois, United States

Oncology Care Associates PLLC; 🇺🇸 Saint Joseph, Michigan, United States

Saint John's Mercy Medical Center; 🇺🇸 Saint Louis, Missouri, United States

London Health Sciences Centre-South Street; 🇨🇦 London, Ontario, Canada

London Regional Cancer Program; 🇨🇦 London, Ontario, Canada

The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus; 🇨🇦 Ottawa, Ontario, Canada

CHUM - Hopital Notre-Dame; 🇨🇦 Montreal, Quebec, Canada

University of Southern California/Norris Cancer Center; 🇺🇸 Los Angeles, California, United States

University of Chicago; 🇺🇸 Chicago, Illinois, United States

Decatur Memorial Hospital; 🇺🇸 Decatur, Illinois, United States

Evanston Hospital CCOP; 🇺🇸 Evanston, Illinois, United States

Loyola University Medical Center; 🇺🇸 Maywood, Illinois, United States

Fort Wayne Medical Oncology and Hematology Inc-Parkview; 🇺🇸 Fort Wayne, Indiana, United States

Northern Indiana Cancer Research Consortium; 🇺🇸 South Bend, Indiana, United States

University of Maryland/Greenebaum Cancer Center; 🇺🇸 Baltimore, Maryland, United States

University of Pittsburgh Cancer Institute; 🇺🇸 Pittsburgh, Pennsylvania, United States

Cancer Centre of Southeastern Ontario at Kingston General Hospital; 🇨🇦 Kingston, Ontario, Canada

University Health Network-Princess Margaret Hospital; 🇨🇦 Toronto, Ontario, Canada

University of California at Davis Cancer Center; 🇺🇸 Sacramento, California, United States

University of Michigan Comprehensive Cancer Center; 🇺🇸 Ann Arbor, Michigan, United States

Medical College of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States

Juravinski Cancer Centre at Hamilton Health Sciences; 🇨🇦 Hamilton, Ontario, Canada